These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 34125179)

  • 41. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
    Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
    Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
    Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
    Kraan W; van Keimpema M; Horlings HM; Schilder-Tol EJ; Oud ME; Noorduyn LA; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Leukemia; 2014 Mar; 28(3):719-20. PubMed ID: 24253023
    [No Abstract]   [Full Text] [Related]  

  • 46. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
    Kraan W; Horlings HM; van Keimpema M; Schilder-Tol EJ; Oud ME; Scheepstra C; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Blood Cancer J; 2013 Sep; 3(9):e139. PubMed ID: 24013661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
    Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
    Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates.
    Shechter R; London A; Schwartz M
    Nat Rev Immunol; 2013 Mar; 13(3):206-18. PubMed ID: 23435332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM
    Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.
    Booman M; Douwes J; Glas AM; Riemersma SA; Jordanova ES; Kok K; Rosenwald A; de Jong D; Schuuring E; Kluin PM
    Clin Cancer Res; 2006 May; 12(9):2698-705. PubMed ID: 16675561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
    Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Delabie J; Ott G; Müller-Hermelink HK; Campo E; Braziel RM; Jaffe ES; Pan Z; Farinha P; Smith LM; Falini B; Banham AH; Rosenwald A; Staudt LM; Connors JM; Armitage JO; Chan WC
    Blood; 2004 Jan; 103(1):275-82. PubMed ID: 14504078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.
    Riemersma SA; Jordanova ES; Schop RF; Philippo K; Looijenga LH; Schuuring E; Kluin PM
    Blood; 2000 Nov; 96(10):3569-77. PubMed ID: 11071656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.
    Minderman M; Amir A; Kraan W; Schilder-Tol EJM; Oud MECM; Scheepstra CG; Noorduyn AL; Kluin PM; Kersten MJ; Spaargaren M; Pals ST
    Blood; 2021 Sep; 138(13):1194-1197. PubMed ID: 34125179
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-L1 Expression in Mastocytosis.
    Williams M; Lidke DS; Hartmann K; George TI
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.